Abstract B128: The impact of race/ethnicity and insurance status on age-related differences in breast cancer survival

Author(s):  
Yazmin San Miguel ◽  
Scarlett L Gomez ◽  
James D Murphy ◽  
Richard B Schwab ◽  
Corinne McDaniels-Davidson ◽  
...  
2013 ◽  
Author(s):  
Alicia Padron ◽  
Tulay Koru-Sengul ◽  
Stacey L. Tannenbaum ◽  
Feng Miao ◽  
Damien Hansra ◽  
...  

2021 ◽  
Vol 30 (7) ◽  
pp. 1408-1415
Author(s):  
Robert B. Hines ◽  
Asal M. Johnson ◽  
Eunkyung Lee ◽  
Stephanie Erickson ◽  
Saleh M.M. Rahman

2019 ◽  
Vol 28 (12) ◽  
pp. 1958-1967 ◽  
Author(s):  
Daniel Wiese ◽  
Antoinette M. Stroup ◽  
Amanda Crosbie ◽  
Shannon M. Lynch ◽  
Kevin A. Henry

Author(s):  
Cynthia Owusu ◽  
Arti Hurria ◽  
Hyman Muss

Overview: Breast cancer is a disease of aging. However, older women with breast cancer are less likely to participate in clinical trials or to receive recommended treatment. This undertreatment has contributed to a lag in breast cancer survival outcomes for older women compared with that for their younger counterparts. The principles that govern recommendations for adjuvant treatment of breast cancer are the same for younger and older women. Systemic adjuvant treatment recommendations should be offered on the basis of tumor characteristics that divide patients into three distinct subgroups. These include (1) older women with hormone receptor (HR)-positive and human epidermal growth factor 2 (HER2)-negative breast cancer who should be offered endocrine therapy; (2) older women with HR-negative and HER2-negative breast cancer who should be offered adjuvant chemotherapy; and (3) older women with HER2-positive disease who should be offered chemotherapy with trastuzumab. Exceptions to these guidelines may be made for older women with small node-negative tumors or frail older women with limited life expectancy, where close surveillance may be a reasonable alternative. Addressing the current age-related disparities in breast cancer survival will require that older women are offered the same state-of-the-art-treatment as their younger counterparts, with a careful weighing of the risks and benefits of each treatment in the context of the individual's preferences. In addition, older women should be encouraged to participate in breast cancer clinical trials to generate additional chemotherapy efficacy, toxicity, and quality of life data.


2020 ◽  
Author(s):  
Kaicheng Wang ◽  
Jennifer J. Hu ◽  
Isildinha M. Reis ◽  
Wei Zhao ◽  
George R. Yang ◽  
...  

2018 ◽  
Vol 25 (5) ◽  
pp. 509-521 ◽  
Author(s):  
Minlu Zhang ◽  
Peng Peng ◽  
Kai Gu ◽  
Hui Cai ◽  
Guoyou Qin ◽  
...  

The impact of some prognostic factors on breast cancer survival has been shown to vary with time since diagnosis. However, this phenomenon has not been evaluated in Asians. In the present study, 4886 patients were recruited from the Shanghai Breast Cancer Survival Study, a longitudinal study of patients diagnosed during 2002–2006, with a median follow-up time of 11.2 years. Cox model incorporating time-by-covariate interactions was used to describe the time-varying effects of prognostic factors related to overall survival and disease-free survival. Age ≥65 years showed a progressively negative effect on breast cancer prognosis over time, whereas tumour size >2 cm had a lasting and constant impact. Age significantly modified the effects of the tumour grade, nodal status and oestrogen receptor (ER) status on breast cancer survival. The detrimental effect of poorly differentiated tumours was time limited and more obvious in patients aged 45–54 years. Having ≥4 positive lymph nodes had a persistent and negative impact on prognosis, although it attenuated in later years; the phenomenon was more prominent in the 55–64-year age group. ER-positive status was protective in the first 3 years after diagnosis but was related to a higher risk of recurrence in later years; the time-point when ER-positive status turned into a risk factor was earlier in younger patients. These results suggest that older age, positive lymph node status, larger tumour size and ER-positive status are responsible for late death or recurrence in Asian breast cancer survivors. Extended endocrine therapy should be given earlier in younger ER-positive patients.


2015 ◽  
Vol 112 (S1) ◽  
pp. S124-S128 ◽  
Author(s):  
M J Rutherford ◽  
G A Abel ◽  
D C Greenberg ◽  
P C Lambert ◽  
G Lyratzopoulos

2013 ◽  
Vol 142 (1) ◽  
pp. 177-185 ◽  
Author(s):  
Adriana Valentini ◽  
◽  
Jan Lubinski ◽  
Tomasz Byrski ◽  
Parviz Ghadirian ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document